Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519
View directory record Official record
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Guselkumab Immunogenetics

NCT04645355
View directory record Official record
Conditions
Psoriasis Guttate, Plaque Psoriasis
Interventions
Guselkumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

NCT03167515
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
074-6751 Lotion
Device
Lead sponsor
Ferndale Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Carmel, Indiana • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 25, 2026, 11:25 AM EDT
Recruiting Phase 4 Interventional

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

NCT05270733
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 25, 2026, 11:25 AM EDT
Completed No phase listed Observational

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

NCT02413749
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Rituxan With or Without Methotrexate in Psoriatic Arthritis

NCT00509678
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Rituximab
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
La Jolla, California • Stanford, California • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

NCT04042103
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Encino, California • Sanford, Florida • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

NCT02601469
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 25, 2026, 11:25 AM EDT
Recruiting No phase listed Observational

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

NCT02418442
View directory record Official record
Conditions
Rheumatic Joint Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 21 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 11:25 AM EDT
Terminated Phase 1 Interventional

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

NCT03662685
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
Goeckerman Therapy, Crude Coal Tar Only, Phototherapy Only
Other · Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 25, 2026, 11:25 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
59
States / cities
Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135
View directory record Official record
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

NCT01892436
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
22
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Not applicable Interventional

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

NCT00705900
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
LCD, calcipotriol
Drug
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris

NCT00235625
View directory record Official record
Conditions
Psoriasis
Interventions
Curcuminoids C3 Complex®
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

NCT02690701
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 11:25 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Psorcast Mobile Study

NCT05621369
View directory record Official record
Conditions
Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Interventions
Participant self-assessment surveys, Psoriasis Draw, Psoriasis Area Photo, Finger and Toe Photos, Digital Jar Open, 30 Second Walk, Psorcast mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 11:25 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

NCT04862286
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 25, 2026, 11:25 AM EDT
Terminated Phase 3 Interventional Results available

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

NCT02322086
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Rose Bengal, 0.005%
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Miami, Florida • Chapel Hill, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 25, 2026, 11:25 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 11:25 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 25, 2026, 11:25 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT07486960
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Sun City, Arizona • Tucson, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 11:25 AM EDT